| | | | | |

Second-Line Mesothelioma Treatment with Ramucirumab

ByAlex Strauss
second-line mesothelioma treatment

A combination of ramucirumab (CYRAMZA) and gemcitabine creates a promising second-line mesothelioma treatment.

New research shows the combination nearly doubled survival in a group of patients whose tumors kept growing with standard therapy. 

Italian researchers shared their findings at the virtual annual meeting of ASCO. ASCO is one of the largest gatherings of cancer doctors in the US.

First-Line Mesothelioma Treatment Failure

For most mesothelioma patients, chemotherapy with Alimta is the first-line treatment. This does keep the cancer in check for some patients. But after a while, mesothelioma tumors almost always come back. Chemotherapy only extends survival by about four months. 

Doctors have tested many different approaches to second-line mesothelioma treatment.  Some of the therapies tested are:

Unfortunately, none of the tested drugs have improved mesothelioma survival by more than eight months. This makes the results of the latest second-line mesothelioma treatment trial especially encouraging.

New Combination for Second-Line Mesothelioma Treatment

The proposed new second-line mesothelioma treatment combines two drugs. The first is gemcitabine. Gemcitabine has been the focus of several drug combination trials for mesothelioma.

Researchers at AUSL-IRCCS Reggio Emilia led the RAMES Study. It combines gemcitabine with ramucirumab (CYRAMZA) for patients who failed standard treatment.

One hundred and sixty-four patients joined the second-line mesothelioma treatment trial. Most trial participants were men with a median age of 69. Most had the epithelioid mesothelioma subtype. 

The trial ran from 2016 to 2018. Eighty-one patients received gemcitabine and a placebo. Eighty patients received gemcitabine and ramucirumab. 

Promising Treatment Results

In the RAMES trial, patients who got gemcitabine and ramucirumab had a median overall survival of 13.8 months. This was significantly longer than the 7.5 months in those who took the placebo combination. 

There were no major differences in the number of blood clots or blood-related toxicities between the two groups. The combo group did have a slightly higher incidence of high blood pressure. This second-line mesothelioma treatment appeared to work independent of other risk factors. 

“The addition of ramucirumab to gemcitabine significantly improved overall survival regardless of age of patients, tumor histotype and time to progression at the first-line treatment,” writes lead investigator Maria Pagano. 

Dr. Pagano and her colleagues conclude that the combination “can be considered a manageable regimen in second-line treatment of advanced malignant pleural mesothelioma patients.”

Next, the team will determine if the treatment improves quality of life for mesothelioma patients. They will also try to determine if people with certain mutated genes respond better than others. 

Sources:

Pagana, et al, “Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study”, May 2020, ASCO Meeting Library, https://meetinglibrary.asco.org/record/184551/abstract

“Ramucirumab–gemcitabine encouraging in second-line malignant pleural mesothelioma”, June 18, 2020, ASCO 2020 news release, https://www.medwirenews.com/oncology/respiratory/ramucirumab-gemcitabine-malignant-pleural-mesothelioma/18096212

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    ByAlex Strauss

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…